Table 2.

Differences in the clinic-pathologic features of subungual (n = 42) and acral (n = 64) melanomas including in situ lesions.

	No. (%)	Subungual	Acral	p
Sex				0.810
Male	52 (49.1)	20 (47.6)	32 (50.0)
Female	54 (50.9)	22 (52.4)	32 (50.0)
Age (years)				0.009
≤63	49 (46.2)	26 (61.9)	23 (35.9)
>63	57 (53.8)	16 (38.1)	41 (64.1)
Tumor location				0.000
Upper	41 (38.7)	29 (69.0)	12 (18.8)
Lower	65 (61.3)	13 (31.0)	52 (81.3)
Invasion of the dermis				0.004
In situ melanoma	17 (16.0)	12 (28.6)	5 (7.8)
Invasive melanoma	89 (84.0)	30 (71.4)	59 (92.2)
Breslow thickness				0.037
In situ	17 (16.0)	12 (28.6)	5 (7.8)
<1 mm	27 (25.5)	12 (28.6)	15 (23.4)
1.01–2.00 mm	15 (14.2)	4 (9.5)	11 (17.2)
2.01–4.00 mm	19 (17.9)	5 (11.9)	14 (21.9)
>4.00 mm	28 (26.4)	9 (21.4)	19 (29.7)
Lymph node metastasis at the time of diagnosis				0.944
Absent	88 (83.0)	35 (83.3)	53 (82.8)
Present	18 (17.0)	7 (16.7)	11 (17.2)
Distant metastasis at the time of diagnosis				0.821
Absent	103 (97.2)	41 (97.6)	62 (96.9)
Present	3 (2.8)	1 (2.4)	2 (3.1)
Stage group				0.016
0	17 (16.0)	12 (28.6)	5 (7.8)
I–II	70 (66.0)	23 (54.8)	47 (73.4)
III–IV	19 (17.9)	7 (16.7)	12 (18.8)
Immunotherapy				0.696
Not carried out	76 (71.7)	31 (73.8)	45 (70.3)
Carried out	30 (28.3)	11 (26.2)	19 (29.7)
Trauma				0.005
Absent	101 (95.3)	37 (88.1)	64 (100.0)
Present	5 (4.7)	5 (11.9)	0 (0.0)
Ulceration				0.226
Absent	71 (67.0)	31 (73.8)	40 (62.5)
Present	35 (33.3)	11 (26.2)	24 (37.5)
Loco-regional recurrence				0.056
Absent	93 (87.7)	40 (95.2)	53 (82.8)
Present	13 (12.3)	2 (4.8)	11 (17.2)
Distant metastasis during the follow-up				0.622
Absent	78 (73.6)	32 (76.2)	46 (71.9)
Present	28 (26.4)	10 (23.8)	18 (21.6)